US Broker Ratings

Sarepta Therapeutics (SRPT) Stock Analysis: Navigating the Biotech Terrain with a 1.36% Potential Upside

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a key player in the biotechnology sector, offers a compelling yet complex investment narrative for those interested in the healthcare industry. With a focus on..

The Cooper Companies, Inc. (COO) Stock Analysis: A Look at Its 46% Potential Upside

The Cooper Companies, Inc. (NYSE: COO), a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry, presents a compelling opportunity for investors with its current..

BrightSpring Health Services (BTSG) Stock Analysis: Strong Buy Ratings and 7.73% Potential Upside

BrightSpring Health Services, Inc. (BTSG) is making waves in the healthcare sector, specifically within the health information services industry. As a prominent player in delivering comprehensive pharmacy and provider services..

Humana Inc. (HUM) Stock Analysis: Navigating Healthcare Growth with a 2.94% Upside Potential

Humana Inc. (NYSE: HUM), a prominent player in the healthcare plans industry, is capturing investor attention with its robust revenue growth and a strategic focus on expanding its service offerings...

Doximity, Inc. (DOCS) Stock Analysis: Analyst Ratings Suggest 51% Potential Upside in Healthcare Tech

Doximity, Inc. (NYSE: DOCS), a prominent player in the healthcare technology sector, is capturing the attention of individual investors with an impressive potential upside of 51.21%, based on analyst ratings...

Prestige Consumer Healthcare (PBH) Stock Analysis: Exploring a Promising 42% Upside Potential

Prestige Consumer Healthcare Inc. (PBH) stands out in the healthcare sector with a robust portfolio of over-the-counter (OTC) health and personal care products. Based in Tarrytown, New York, Prestige operates..

Smith & Nephew SNATS, Inc. (SNN) Investor Outlook: Navigating a 15.73% Potential Upside in the Medical Device Sector

Smith & Nephew SNATS, Inc. (NYSE: SNN), a prominent player in the healthcare sector, particularly in the medical devices industry, is currently presenting a compelling opportunity for investors looking to..

Glaukos Corporation (GKOS) Stock Analysis: Healthcare Innovator with 7.75% Upside Potential

Glaukos Corporation (NYSE: GKOS), a prominent player in the healthcare sector specializing in medical devices, has been capturing investor attention with its innovative approach to treating ophthalmic conditions. The company,..

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Close Look at the Biotechnology Innovator’s Market Position and Potential

Soleno Therapeutics, Inc. (NASDAQ: SLNO) stands at the forefront of the biotechnology sector, focusing on the development of novel therapeutics for rare diseases. With a market capitalization of $2.73 billion,..

Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring an 86% Potential Upside in RNA Therapeutics

Atrium Therapeutics, Inc. (NASDAQ: RNA), a promising player in the biotechnology sector, is capturing investor attention with a striking 86.15% potential upside, according to analyst ratings. This San Diego-based biopharmaceutical..

Molina Healthcare Inc (MOH) Stock Analysis: Navigating a Challenging Market with Strategic Resilience

Molina Healthcare Inc (MOH), a stalwart in the healthcare plans industry, is a significant player in the U.S. healthcare market, providing managed healthcare services to low-income families and individuals. Operating..

Qiagen N.V. (QGEN) Investor Outlook: Exploring a 39.20% Potential Upside

As an integral player in the healthcare sector, Qiagen N.V. (NYSE: QGEN) operates in the diagnostics and research industry, providing transformative solutions that convert biological samples into molecular insights. Headquartered..

HCA Healthcare, Inc. (HCA) Stock Analysis: A Look at the 18.47% Upside Potential and Analyst Ratings

HCA Healthcare, Inc. (NYSE: HCA) stands as a formidable entity within the healthcare sector, specifically in the medical care facilities industry. With its headquarters nestled in Nashville, Tennessee, HCA Healthcare..

Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A 14% Potential Upside with Robust CNS Pipeline

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is making waves in the biotechnology sector with its focus on developing innovative therapies for central nervous system (CNS) disorders. With a market capitalization of..

Waters Corporation (WAT) Stock Analysis: Exploring a Potential 25.52% Upside for Investors

Waters Corporation (NYSE: WAT), a prominent player in the Healthcare sector’s Diagnostics & Research industry, is capturing investor attention with a potential upside of 25.52%. This potential growth is highlighted..

Revolution Medicines, Inc. (RVMD) Stock Analysis: Navigating a 24.96% Upside in the Biotech Sector

Revolution Medicines, Inc. (NASDAQ: RVMD) is a formidable player in the biotechnology sector, with a focus on precision oncology. Specializing in developing targeted therapies for RAS-addicted cancers, the company is..

Eli Lilly and Company (LLY)

⚠️ No article content returned.

..

HealthEquity, Inc. (HQY) Stock Analysis: Robust Growth Potential with 36.98% Upside

HealthEquity, Inc. (NASDAQ: HQY), a prominent player in the healthcare information services industry, is grabbing the attention of savvy investors with its significant growth potential and robust market positioning. With..

Alkermes plc (ALKS) Stock Analysis: Exploring a 33% Upside Potential Amidst Diverse Product Portfolio

Alkermes plc (NASDAQ: ALKS) is capturing investor attention with its potential upside of 33.40%, as indicated by its average target price of $44.53. This Ireland-based biopharmaceutical company operates in the..

AbbVie Inc. (ABBV): Investor Outlook with 21% Potential Upside and Strong Buy Ratings

Investors with an eye on the healthcare sector may find AbbVie Inc. (NYSE: ABBV) an enticing opportunity. With a market capitalization of $365.43 billion, this U.S.-based biopharmaceutical giant remains a..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds